“FLOW Trial: Semaglutide and 24% Fewer Kidney Events The first dedicated GLP-1 kidney-outcomes trial in type 2 diabetes and CKD” (2026) Diabzen, 4(20), pp. 40–41. Available at: https://www.thediabzen.com/index.php/d/article/view/63 (Accessed: 17 September 2026).